Compare PLSE & AAPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PLSE | AAPG |
|---|---|---|
| Founded | 2014 | 2009 |
| Country | United States | China |
| Employees | N/A | 767 |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 2.0B |
| IPO Year | 2015 | N/A |
| Metric | PLSE | AAPG |
|---|---|---|
| Price | $24.48 | $19.50 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | $22.00 | ★ $48.40 |
| AVG Volume (30 Days) | ★ 351.3K | 6.3K |
| Earning Date | 05-07-2026 | 05-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $840.00 | $290.34 |
| Revenue Next Year | $287.54 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.56 | $18.56 |
| 52 Week High | $27.98 | $48.45 |
| Indicator | PLSE | AAPG |
|---|---|---|
| Relative Strength Index (RSI) | 54.28 | 41.87 |
| Support Level | $17.58 | $18.56 |
| Resistance Level | $27.14 | $25.23 |
| Average True Range (ATR) | 1.82 | 0.88 |
| MACD | 0.04 | 0.11 |
| Stochastic Oscillator | 60.69 | 37.06 |
Pulse Biosciences Inc is a novel bioelectric medicine company committed to health innovation using its patented Nano-Pulse Stimulation technology, a revolutionary energy modality that delivers nanosecond-duration pulses of electrical energy, each less than a millionth of a second long, to non-thermally clear targeted cells while sparing adjacent noncellular tissue. NPS technology, also referred to as Nanosecond Pulsed Field Ablation (nsPFA) technology delivers nanosecond pulses of electrical energy to nonthermally clear cells while sparing adjacent noncellular tissue.
Ascentage Pharma Group International is a clinical-stage biotechnology company engaged in the development and sales of novel small-scale therapies for cancers, hepatitis B virus, or HBV, and certain age-related diseases. It focuses on developing therapies that inhibit protein-protein interactions to restore apoptosis or programmed cell death. The Group has one reportable operating segment, which is discovering, developing, and commercializing therapies to address medical needs in hematological malignancies and currently has seven drug candidates in pipeline under research. The company's geographical segments include the United States and Mainland China.